Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Dulaglutide (Trulicity) vs Lixisenatide (Adlyxin)
An educational, source-based comparison of Dulaglutide (Trulicity) and Lixisenatide (Adlyxin) — how each peptide works, what it's researched for, and what to know before going deeper.
Once-weekly GLP-1 agonist with cardiovascular benefit.
GLP-1 analog fused to a modified human IgG4 Fc fragment, giving a half-life that supports weekly dosing. Improves glycemia and reduces MACE in T2D.
- Type 2 diabetes
- Cardiovascular risk reduction in T2D
- • FDA-approved.
- • Boxed warning: thyroid C-cell tumors in rodents.
Short-acting GLP-1 agonist focused on postprandial glucose.
Exendin-4 derivative with potent postprandial glucose-lowering effect via delayed gastric emptying and enhanced insulin response.
- Type 2 diabetes
- Postprandial hyperglycemia
- • FDA-approved.
- • GI side effects common.
Dulaglutide (Trulicity) vs Lixisenatide (Adlyxin) — Key differences
- Class: Dulaglutide (Trulicity) is classified as GLP-1 Agonist · Metabolic, while Lixisenatide (Adlyxin) is GLP-1 Agonist · Metabolic.
- Primary research focus: Dulaglutide (Trulicity) — type 2 diabetes; Lixisenatide (Adlyxin) — type 2 diabetes.
- Tag: FDA-Approved · Metabolic vs FDA-Approved · Metabolic.